Literature DB >> 7994759

Suppression of HIV replication by CD8+ cell clones derived from HIV-infected and uninfected individuals.

F W Hsueh1, C M Walker, D J Blackbourn, J A Levy.   

Abstract

CD8+ cell clones have been derived from peripheral blood mononuclear cells of human immunodeficiency virus (HIV)-infected and uninfected individuals. Several of these cloned cells have the ability to suppress HIV replication when cocultured with CD4+ cells acutely infected in the laboratory with HIV or with infected CD4+ cells from infected subjects. Suppression of virus production occurs without killing the target cells. With the CD8+ cell clones studied, this antiviral response correlated with production of a filterable factor that has antiviral activity. These cell clones offer the opportunity for identification of the factor mediating suppression of HIV replication. Moreover, adoptive transfer of cell clones might provide a valuable therapeutic approach for HIV-infected individuals.

Entities:  

Mesh：

Year:  1994        PMID： 7994759     DOI： 10.1006/cimm.1994.1313

Source DB:  PubMed          Journal:  Cell Immunol        ISSN： 0008-8749            Impact factor:   4.868


  11 in total

Review 1.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

2.  HIV-1-specific cell-mediated immunity is enhanced by co-inoculation of TCA3 expression plasmid with DNA vaccine.

Authors:  T Tsuji; J Fukushima; K Hamajima; N Ishii; I Aoki; H Bukawa; Y Ishigatsubo; K Tani; T Okubo; M E Dorf; K Okuda
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

Review 3.  Immune dysregulation and CD4+ T cell loss in HIV-1 infection.

Authors:  L Meyaard; F Miedema
Journal:  Springer Semin Immunopathol       Date:  1997

4.  CD8(+)-Cell antiviral factor activity is not restricted to human immunodeficiency virus (HIV)-specific T cells and can block HIV replication after initiation of reverse transcription.

Authors:  S Le Borgne; M Février; C Callebaut; S P Lee; Y Rivière
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

5.  In vivo T-lymphocyte activation and transient reduction of viral replication in macaques infected with simian immunodeficiency virus.

Authors:  Z W Chen; Y Shen; D Zhou; M Simon; Z Kou; D Lee-Parritz; L Shen; P Sehgal; N L Letvin
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

6.  Changes in soluble factor-mediated CD8+ cell-derived antiviral activity in cynomolgus macaques infected with simian immunodeficiency virus SIVmac251: relationship to biological markers of progression.

Authors:  Vincent Dioszeghy; Kadija Benlhassan-Chahour; Benoit Delache; Nathalie Dereuddre-Bosquet; Celine Aubenque; Gabriel Gras; Roger Le Grand; Bruno Vaslin
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

7.  Natural suppression of human immunodeficiency virus type 1 replication is mediated by transitional memory CD8+ T cells.

Authors:  M Scott Killian; Carl Johnson; Fernando Teque; Sue Fujimura; Jay A Levy
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

8.  Intranasal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1.

Authors:  K Q Xin; K Hamajima; S Sasaki; A Honsho; T Tsuji; N Ishii; X R Cao; Y Lu; J Fukushima; P Shapshak; S Kawamoto; K Okuda
Journal:  Immunology       Date:  1998-07       Impact factor: 7.397

9.  Noncytotoxic suppression of human immunodeficiency virus type 1 transcription by exosomes secreted from CD8+ T cells.

Authors:  Ashwin Tumne; Varsha Shridhar Prasad; Yue Chen; Donna B Stolz; Kunal Saha; Deena M Ratner; Ming Ding; Simon C Watkins; Phalguni Gupta
Journal:  J Virol       Date:  2009-02-04       Impact factor: 5.103

10.  Consequences of cytotoxic T lymphocyte interaction with major histocompatibility complex class I-expressing neurons in vivo.

Authors:  G F Rall; L Mucke; M B Oldstone
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.